Clinical Trials Logo
  1. Home
  2. Glioblastoma Multiforme, Adult
  3. NCT05333588

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Glioblastoma Multiforme, Adult Clinical Trial

Official title:
The Safety and Efficacy Study of Autologous Tumor-infiltrating Lymphocyte (TILs) Therapy Combined With Conventional Chemotherapy for Patients With Advanced Stage of Glioblastoma Multiforme.

Clinical Trial Summary

The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05333588
Study type Interventional
Source Hebei Senlang Biotechnology Inc., Ltd.
Contact Na Kuang
Phone +8618630160116
Email kuangna@senlangbio.com
Status Recruiting
Phase Early Phase 1
Start date February 15, 2022
Completion date February 15, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04762069 - A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Phase 2
Recruiting NCT04869449 - Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas Early Phase 1
Withdrawn NCT03480867 - Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA) Phase 1
Not yet recruiting NCT05653622 - Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma Phase 2
Recruiting NCT05954858 - Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma N/A
Recruiting NCT05052957 - hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) Phase 2
Recruiting NCT05977738 - Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin Early Phase 1
Recruiting NCT04614909 - Study of Pamiparib in Newly Diagnosed and rGBM Early Phase 1
Recruiting NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Recruiting NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Recruiting NCT06146738 - The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Recruiting NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Recruiting NCT04825275 - Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial Early Phase 1
Recruiting NCT05565521 - UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly Phase 2
Completed NCT05671016 - Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy
Recruiting NCT05271240 - Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM Phase 3
Recruiting NCT04469699 - Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma Phase 2
Recruiting NCT05720078 - UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) N/A